Compare BBY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | BIIB |
|---|---|---|
| Founded | 1966 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | BBY | BIIB |
|---|---|---|
| Price | $74.02 | $181.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 23 |
| Target Price | $84.24 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 4.1M | 1.9M |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.02 | ★ 10.97 |
| Revenue | ★ $41,825,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $1.77 | $3.61 |
| Revenue Next Year | $1.32 | N/A |
| P/E Ratio | $24.54 | ★ $16.52 |
| Revenue Growth | N/A | ★ 4.77 |
| 52 Week Low | $54.99 | $110.04 |
| 52 Week High | $91.68 | $185.17 |
| Indicator | BBY | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 72.92 |
| Support Level | $74.24 | $174.53 |
| Resistance Level | $83.67 | $182.94 |
| Average True Range (ATR) | 2.59 | 5.22 |
| MACD | -0.30 | 0.25 |
| Stochastic Oscillator | 11.07 | 83.54 |
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).